Kite, a Gilead Company, announced detailed results from the overall survival (OS) analysis of the landmark phase 3 ZUMA-7 study of Yescarta® (axicabtagene ciloleucel) CAR T-cell therapy compared with historical standard of care (SOC) as initial treatment in the curative setting...
Yescarta® demonstrates significantly longer OS versus standard of care as initial treatment of R/R LBCL
